ACHV logo

ACHIEVE LIFE SCIENCES INC

ACHVNASDAQ
🏆 #2655 by market capEarnings Nov 5US Equity
$742.93▲ $40.42 (+5.44%)
Simulated price
🔔
Track ACHV
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 5.4%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$789M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
64
Fair
No chart data available for ACHV.

Trading Snapshot

Day Range
$736.40 – $753.76
52-Week Range
$2.62 – $8.64
Volume
$2.84B
Avg Volume
$2.57B
Shares Outstanding
102.7M
Next Earnings
Dec 7, 2026

Fundamentals Snapshot

Annual Revenue
$138M
Last Q Revenue
$33M
P/E Ratio
-5.0
P/S Ratio
0.0x
EPS (TTM)
$-1.22
Dividend Yield
0.00%
Dilution (1yr)
+54.4%

Why Investors Own ACHV

  • ✓High-growth profile — revenue up +55.9% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 74% gross margin and 18% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ACHV logo

ACHIEVE LIFE SCIENCES INC

ACHV
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$55M▲ +40.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$49M▲ +66.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
53.3M▲ +54.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$6M▲ +$3M YoY
StockOtter · stockotter.space

About ACHIEVE LIFE SCIENCES INC

Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
64/100

Analyst Price Target

ⓘ
Average Target
$909.14
▲ +22.4% Upside
High Target$989.82
Low Target$746.46
Based on 24 analysts

Latest News & Updates

🚀
MarketWatch·2h ago

ACHIEVE LIFE SCIENCES INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift ACHV price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatch·1d ago

ACHIEVE LIFE SCIENCES INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.